ArticleMolecular and cellular biochemistry2016
Ubiquitin-specific protease 39 is overexpressed in human lung cancer and promotes tumor cell proliferation in vitro.
Article in Molecular and cellular biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Clinicopathological and Prognostic Significance of Ubiquitin-Specific Protease 39 Overexpression in solid Cancers: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- USP39 promote post-translational modifiers to stimulate the progress of cancer.Discover oncology · 2025Review
- Exploring the cancerous nexus: the pivotal and diverse roles of USP39 in cancer development.Discover oncology · 2025Review
- Identification of USP39 as a prognostic and predictive biomarker for determining the response to immunotherapy in pancreatic cancer.BMC cancer · 2025Article
- USP39 at the crossroads of cancer immunity: regulating immune evasion and immunotherapy response through RNA splicing and ubiquitin signaling.Frontiers in immunology · 2025Review
- USP39: a key regulator in malignant tumor progression.Frontiers in oncology · 2025Review
- USP39 regulates pyruvate handling in non-small cell lung cancer.Cell death discovery · 2024Article
- miR-381 Inhibits Proliferation and Invasion of Non-Small-Cell Cancer Cells by Targeting USP39.Disease markers · 2022Article
- USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-ACancer cell international · 2021Article
- The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer.International journal of molecular sciences · 2021Review
- Identifying Novel Actionable Targets in Colon Cancer.Biomedicines · 2021Review
- The Deubiquitinase USP39 Promotes ESCC Tumorigenesis Through Pre-mRNA Splicing of the mTORC2 Component Rictor.Frontiers in oncology · 2021Article
- Knocking down USP39 Inhibits the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through Activating the p53 Pathway.International journal of molecular sciences · 2020Article
- Stabilization of the histone acetyltransferase Tip60 by deubiquitinating enzyme USP7 stimulates the release of pro-inflammatory mediators in acute lung injury.Journal of molecular medicine (Berlin, Germany) · 2020Article
- RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation.Oncogene · 2019Article
- A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer.International journal of clinical and experimental pathology · 2019Article
- miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most frequent cancer in the world. Previous studies have shown that ubiquitin-specific protease 39 (USP39) is upregulated in several cancers and associated with tumor malignant characters. However, the effects of USP39 in lung cancer have not been well understood. In the present study, we found USP39 was generally expressed higher in human lung cancer tissues than in normal tissues by Oncomine database mining, qRT-PCR, and western blot assay. Knockdown of USP39 expression markedly reduced the proliferative and colony-forming ability of lung cancer cell lines 95D and A549. Flow cytometric analysis showed that USP39 knockdown induced cell cycle arrest at G2/M phase and enhanced cell apoptosis in 95D cells. Moreover, depletion of USP39 blocked activation of Akt, mTOR, p53, and PARP signaling pathways. Taken together, our study indicates that USP39 may be functionally involved in lung cancer growth and act as a potential molecular target for human lung cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.